• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [535 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2016 Adelaide Health Technology Assessment (AHTA) Cardiac MRI for myocardial stress perfusion and viability imaging in patients with known or suspected coronary artery disease
2016 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) MicroVisualase Thermal Therapy System: MRI-guided laser ablation of neurologic tumourswave ablation for liver tumours
2016 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Ga-68 prostate specific membrane antigen (PSMA) PET/CT
2016 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Cardiac MRI for myocardial stress perfusion and viability imaging in patients with known or suspected coronary artery disease
2016 The Regional Health Technology Assessment Centre (HTA-centrum) Positron emission tomography and computed tomographic imaging prior to radiotherapy for lung cancer
2016 The Regional Health Technology Assessment Centre (HTA-centrum) Positron emission tomography and computed tomographic imaging prior to radiotherapy for anal cancer
2015 NIHR Health Technology Assessment programme Computed tomographic colonography compared with colonoscopy or barium enema for diagnosis of colorectal cancer in older symptomatic patients: two multicentre randomised trials with economic evaluation (the SIGGAR trials)
2015 Haute Autorite de sante (HAS) [Assessment of cardiovascular magnetic resonance compared to coronography and computed tomography]
2015 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [PET-CT: needs assessment for planning]
2015 Medical Services Advisory Committee (MSAC) Optical coherence tomography (OCT) for retinal assessment in the presence of diabetic macular oedema (DMO) for access to treatment with dexamethasone posterior segment drug delivery system
2015 Medical Services Advisory Committee (MSAC) F-18 Fluorodeoxyglucose positron emission tomography (FDG PET) for the diagnosis of Alzheimer's disease
2015 HAYES, Inc. MRI-TRUS fusion-guided biopsy for the diagnosis of prostate cancer
2015 NIHR Horizon Scanning Centre (NIHR HSC) ClearSight™ MRI for breast cancer lumpectomy
2015 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Opportunities and strategies to drive appropriate use of MRI in Austria. Part 2]
2015 Andalusian Health Technology Assessment Area (AETSA) FDG-PET/CT and SPECT for cancer staging.
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) ViewRay System for MRI guided radiotherapy
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Optical coherence tomography (OCT) for retinal assessment in the presence of diabetic macular oedema (DMO) for access to treatment with dexamethasone posterior segment drug delivery system
2015 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) MRI liver - scan for the detection and characterisation of focal liver lesions
2015 National Institute for Health and Care Excellence (NICE) Low energy contact X-ray brachytherapy (the Papillon technique) for early stage rectal cancer. NICE interventional procedures guidance 532
2014 NIHR Health Technology Assessment programme Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation
2014 HAYES, Inc. Positron Emission Tomography (PET) for metastatic melanoma
2014 NIHR Horizon Scanning Centre (NIHR HSC) The ViewRay™ System for MRI-guided radiotherapy
2014 NIHR Horizon Scanning Centre (NIHR HSC) Strokefinder MD100 microwave tomography for early diagnosis of stroke type
2014 Institut national d'excellence en sante et en services sociaux (INESSS) [Real-time magnetic resonance imaging (MRI)-guided radiation therapy]
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Diagnostic computed tomography angiography for adult patients: safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Mobile x-ray imaging versus fixed x-ray imaging in long-term care: clinical and cost-effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Computed tomography scanners for patients in rural or remote locations: clinical and cost-effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Positron emission tomography in neurology and cardiology: a review of guidelines and recommendations
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Computed tomography-guided brachytherapy treatment in the operating room: clinical effectiveness, cost-effectiveness, and guidelines
2014 Health Quality Ontario (HQO) Optical coherence tomography monitoring strategies for A-VEGF–treated age-related macular degeneration: an evidence-based analysis
2014 Health Quality Ontario (HQO) Optical coherence tomography monitoring strategies for A-VEGF–treated age-related macular degeneration: OHTAC recommendation
2014 National Evidence-based Healthcare Collaborating Agency (NECA) [Diagnostic usefulness of brain FDG-PET for Alzheimer's dementia]
2014 National Evidence-based Healthcare Collaborating Agency (NECA) [Health Technology Assessment on diagnostic testing: Cardiac MRI and MRSA genetic testing (Real-time polymerase chain reaction)]
2014 NIHR Horizon Scanning Centre (NIHR HSC) LiverMultiScan™ multiparametric MRI for liver disease
2014 HAYES, Inc. Combined positron emission tomography-computed tomography (PET-CT) for evaluating esophageal cancer
2014 HAYES, Inc. Combined positron emission tomography-computed tomography (PET-CT) for evaluating gastric and colorectal cancers
2014 HAYES, Inc. Magnetic resonance imaging (MRI) for surveillance for breast cancer recurrence following mastectomy and breast reconstruction
2014 Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Review of positron emission tomography (PET) indications. Appropriate use criteria]
2014 Adelaide Health Technology Assessment (AHTA) Bone mineral density analyses using dual energy x-ray absorptiometry (DXA) for women in their 50th year
2014 Adelaide Health Technology Assessment (AHTA) Computed tomography colonography for the diagnosis or exclusion of colorectal neoplasia
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Radiation emissions from computed tomography: a review of the risk of cancer and guidelines
2014 HAYES, Inc. Choline PET and PET-CT for suspected recurrent prostate cancer
2014 HAYES, Inc. Computed tomography-guided percutaneous microwave ablation for lung nodules
2014 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Opportunities and strategies to drive appropriate use of MRI in Austria
2014 Medical Services Advisory Committee (MSAC) Cone beam computer tomography (CBCT) for dental/craniofacial imaging
2014 Medical Services Advisory Committee (MSAC) Magnetic Resonance Imaging (MRI) for small bowel and pelvis in Crohn disease
2014 Medical Services Advisory Committee (MSAC) Review of interim funded service: breast Magnetic Resonance Imaging (MRI)
2014 Medical Services Advisory Committee (MSAC) Bone mineral density analyses using Dual Energy X-Ray Absorptiometry (DXA) in breast cancer patients receiving aromatase inhibitor treatment
2014 Institute of Health Economics (IHE) Low dose computed tomography for the screening of lung cancer in adults
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Computed tomography imaging for the diagnosis of renal colic: a review of clinical and cost-effectiveness
2014 Malaysian Health Technology Assessment (MaHTAS) Cone beam computed tomography
2014 Basque Office for Health Technology Assessment (OSTEBA) [Use of radiography in diagnosing low back pain: systematic review]
2014 National Institute for Health and Care Excellence (NICE) Optical coherence tomography to guide percutaneous coronary intervention. NICE interventional procedures guidance 481
2013 Medical Services Advisory Committee (MSAC) Optical coherence tomography, for the diagnosis and monitoring of treatment effectiveness with aflibercept in patients with central retinal vein occlusion (co-dependent)
2013 NIHR Health Technology Assessment programme Improving the economic value of photographic screening for optical coherence tomography-detectable macular oedema: a prospective, multicentre, UK study
2013 NIHR Health Technology Assessment programme Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling
2013 NIHR Health Technology Assessment programme A systematic review and economic evaluation of new-generation computed tomography scanners for imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, Aquilion ONE, Brilliance iCT and Discovery CT750 HD
2013 NIHR Health Technology Assessment programme Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis
2013 HAYES, Inc. Positron Emission Tomography (PET) and Combined Positron Emission Tomography-Computed Tomography (PET-CT) for the posttreatment management of cancer of the head and neck
2013 Scottish Health Technologies Group (SHTG) Does the addition of positron emission tomography/computed tomography (PET/CT) to the routine investigation and assessment of patients with melanoma yield clinical and economic benefits?
2013 Scottish Health Technologies Group (SHTG) Does the addition of positron emission tomography/computed tomography (PET/CT) to the routine investigation and assessment of patients with sarcoidosis yield clinical and economic benefits?
2013 Scottish Health Technologies Group (SHTG) What is the sensitivity and specificity of PET/CT compared with other diagnostic imaging modalities in determining the cause of pyrexia of unknown origin (PUO)? What is the clinical and cost effectiveness of PET/CT as a first-line investigation in patients with PUO?
2013 Scottish Health Technologies Group (SHTG) PET/CT for the inversitgation of paraneoplastic syndromes (PNS)
2013 Scottish Health Technologies Group (SHTG) Is cone beam computed tomography (CBCT) clinically effective, cost-effective and safe compared with standard extraoral and intraoral radiography in the diagnosis of hard tissue pathology in routine dental practice?
2013 HAYES, Inc. Low-dose helical (spiral) computed tomography for lung cancer screening
2013 HAYES, Inc. Computed Tomography (CT)-guided lung biopsy with the superDimension i-Logic System (Covidien)
2013 NIHR Horizon Scanning Centre (NIHR HSC) Etanercept (Enbrel) for axial spondyloarthritis without radiographic evidence of ankylosing spondylitis
2013 Andalusian Health Technology Assessment Area (AETSA) [Efficacy, safety and efficiency of computed tomographic colonography vs. colonoscopy as colorectal cancer screening test]
2013 Andalusian Health Technology Assessment Area (AETSA) [Effectiveness and safety of MRI 3 tesla versus MRI 1.5 tesla. Systematic Review]
2013 Canadian Agency for Drugs and Technologies in Health (CADTH) Computed tomography guided versus ultrasound guided renal biopsy: comparative evidence
2013 Canadian Agency for Drugs and Technologies in Health (CADTH) Appropriate utilization of advanced diagnostic imaging procedures: CT, MRI, and PET/CT
2013 Institute for Clinical Effectiveness and Health Policy (IECS) [MRI enterography for the assessment of inflammatory bowel disease]
2013 Canadian Agency for Drugs and Technologies in Health (CADTH) Computed tomography angiography versus computed tomography for the diagnosis and management of hyperacute stroke: a review of comparative clinical evidence and guidelines
2013 Canadian Agency for Drugs and Technologies in Health (CADTH) Multi-dose contrast media for patients undergoing computed tomography: clinical benefits, harms, and guidelines
2013 Canadian Agency for Drugs and Technologies in Health (CADTH) Ultrasound versus computed tomography for children with suspected appendicitis: clinical evidence, cost-effectiveness, and guidelines
2013 Canadian Agency for Drugs and Technologies in Health (CADTH) X-ray series for foot and ankle injuries: clinical evidence, cost-effectiveness, and guidelines
2013 Belgian Health Care Knowledge Centre (KCE) Extremity-only MRI
2013 Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Evaluation of efficacy and safety of PET-CT (update)]
2013 Malaysian Health Technology Assessment (MaHTAS) Transcranial Doppler (TCD) ultrasound and cerebral computed tomography perfusion (CTP) for aneurysmal subarachnoid haemorrhage (SAH)
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Positron emission tomography (PET) in oesophagus cancer]
2012 NIHR Health Technology Assessment programme EOS 2D/3D X-ray imaging system: a systematic review and economic evaluation
2012 NIHR Horizon Scanning Centre (NIHR HSC) Hybrid PET/MR systems for whole-body diagnostic imaging
2012 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Role of PET/CT with choline analogue radiotracers in the diagnosis and staging of prostate cancer]
2012 Blue Cross Blue Shield Association (BCBS) Beta amyloid imaging with Positron Emission Tomography (PET) for evaluation of suspected alzheimer's disease or other causes of cognitive decline
2012 National Evidence-based Healthcare Collaborating Agency (NECA) [A systematic review of the diagnostic accuracy of FDG PET/PET-CT for fever of unknown origin]
2012 Agenzia nazionale per i servizi sanitari regionali (Agenas) FDG-PET/CT for cancer staging
2012 Institute for Clinical Effectiveness and Health Policy (IECS) [Positron emission tomography in combination with computed tomography (PET/CT) in minimal cognitive impairment and dementias]
2012 Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR) Criteria for appropriate use of FDG-PET in lung cancer
2012 Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR) Criteria for appropriate use of FDG-PET in malignant lymphoma: Hodgkin's lymphoma, aggressive non-Hodgkin's lymphoma
2012 Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR) Criteria for the appropriate use of positron emission tomography with FDG (FDG-PET) in head and neck cancer
2012 Basque Office for Health Technology Assessment (OSTEBA) [Indications and recommendations for the use of PET-CT in the planning of radiation oncology treatment. Systematic review]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Positron emission tomography (PET) in ovarian cancer]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Positron emission tomography (PET) in recurrent colorectal cancer]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Positron emission tomography (PET) in bone and soft tissue tumors]
2012 Canary Health Service [Systematic review of the economic impact of MRI-guided surgery (update)]
2011 NIHR Health Technology Assessment programme Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation
2011 NIHR Health Technology Assessment programme The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation
2011 NIHR Health Technology Assessment programme An economic evaluation of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence
2011 Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Positron emission tomography: proposal for prioritization of indications]
2011 Committee for New Health Technology Assessment (CNHTA) [C-11-acetate positron emission tomography, positron emission tomography/computed tomography]